Search | Clinical Trials Finder

Conditions: SARS-CoV-2
Interventions: mRNA-1273, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30,415 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 100
States / cities: Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 79 more

Conditions: SARS-CoV Infection, COVID-19, Allergic Reaction, Mast Cell Disorder
Interventions: Moderna COVID-19 Vaccine, Pfizer-BioNTech COVID-19 Vaccine, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 5 Years and older
Enrollment: 746 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 29
States / cities: Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 24 more

Conditions: Covid19, SARS-CoV2 Infection
Interventions: mRNA-1273; Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: SARS-CoV-2
Interventions: mRNA-1283, mRNA-1273, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 5
States / cities: Chandler, Arizona • San Diego, California • Melbourne, Florida + 2 more

Conditions: COVID-19, COVID-19 Immunisation
Interventions: mRNA-1273; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Decatur, Georgia • Bethesda, Maryland • Seattle, Washington

Conditions: SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus, Cytomegalovirus
Interventions: mRNA-1273, mRNA-1010, mRNA-1345, FLUAD®, mRNA-1647; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 308 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 8
States / cities: Hollywood, Florida • Savannah, Georgia • Sioux City, Iowa + 4 more

Conditions: Quality of Life, Injection Site Reaction, Adverse Drug Event, Systemic Reaction
Interventions: mRNA COVID-19, IIV4, Placebo (saline); Biological · Other
Lead sponsor: Duke University; Other
Eligibility: 5 Years and older
Enrollment: 348 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Baltimore, Maryland • Durham, North Carolina • Cincinnati, Ohio

Conditions: COVID-19, COVID-19 Immunisation
Interventions: mRNA-1273, mRNA-1273.351; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Decatur, Georgia • Cincinnati, Ohio • Nashville, Tennessee + 1 more

Conditions: Covid19, Vaccine Reaction
Interventions: COVID-19 vaccine; Drug
Lead sponsor: Huntington Memorial Hospital; Other
Eligibility: Not listed
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Pasadena, California

Conditions: COVID-19
Interventions: Moderna COVID-19 Vaccine, Moderna mRNA1273.222 Booster, Pfizer COVID-19 Vaccine, Moderna 2023 Updated COVID-19 vaccine (XBB.1.5), Pfizer 2023 Updated COVID-19 vaccine (XBB.1.5); Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,713 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Culver City, California

Conditions: Influenza Immunization, Healthy Volunteers
Interventions: Quadrivalent Inactivated Influenza High Dose, COVID-19 mRNA Vaccine (nucleoside modified); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 65 Years and older
Enrollment: 306 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 6
States / cities: Glendale, Arizona • San Diego, California • Vista, California + 3 more

Conditions: COVID-19 Vaccines
Interventions: COVID-19 vaccines; Biological
Lead sponsor: Mebo Research, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Miami, Florida • Vonore, Tennessee

Conditions: SARS-CoV-2
Interventions: mRNA-1273, Placebo, mRNA-1273.214; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 6 Months to 11 Years
Enrollment: 11,942 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 83
States / cities: Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 68 more

Conditions: COVID-19 Pneumonia, COVID-19
Interventions: Pfizer COVID-19 mRNA vaccine, Moderna COVID-19 mRNA vaccine; Biological
Lead sponsor: Methodist Health System; Other
Eligibility: 18 Years to 100 Years
Enrollment: 100 participants
Timeline: 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: SARS-CoV-2
Interventions: mRNA-1283, mRNA-1273; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 6 Months to 11 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 13
States / cities: Ontario, California • Miami, Florida • Miami Lakes, Florida + 9 more

Conditions: SARS-CoV-2
Interventions: Biological: mRNA-1273, Placebo, mRNA-1273.351; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 660 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 8
States / cities: Savannah, Georgia • Newton, Kansas • Kansas City, Missouri + 5 more

Conditions: COVID-19, Long Haul
Interventions: Ritonavir-Boosted Nirmatrelvir (Paxlovid), Physiological Evaluation, Moderna COVID-19 Vaccine, Biopsychological, Behavioral (e.g., Psychotherapy, Lifestyle Counseling), Genetic (including gene transfer, stem cell and recombinant DNA), Multidisciplinary approach; Drug · Diagnostic Test · Biological + 3 more
Lead sponsor: Well- Konnect Healthcare Services and Research Firm; Network
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: COVID-19, Corona Virus Infection
Interventions: Pfizer-BioNTech mRNA COVID-19 vaccine, Moderna mRNA COVID-19 vaccine; Biological
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Herpes Zoster
Interventions: HZ/su, Flu D-QIV, mRNA-1273; Biological · Combination Product
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 2,013 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 46
States / cities: Tempe, Arizona • Oxnard, California • San Diego, California + 40 more

Conditions: Lung Transplant Recipient, SARS-CoV-2, Immunosuppression
Interventions: mRNA-1273 (Moderna COVID-19 vaccine); Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Covid19
Interventions: Moderna mRNA-1273 COVID-19 vaccine, Pfizer BNT162b2 COVID-19 vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 16
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 11 more

Conditions: SARS-CoV-2
Interventions: mRNA-1273; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 15
States / cities: Mesa, Arizona • San Diego, California • New Haven, Connecticut + 12 more

Conditions: Cancer
Interventions: COVID-19 Vaccination; Biological
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 2,206 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Carmel, Indiana • Indianapolis, Indiana

Conditions: COVID-19
Interventions: Ad26.COV2.S, BNT162b2, mRNA-1273, mRNA-1273.211, mRNA-1273.222, SARS-CoV-2 rS/M1; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 867 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 10
States / cities: Decatur, Georgia • Baltimore, Maryland • New York, New York + 6 more

Search by objective public record fields.

A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19

COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations

COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients

A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19

Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)

A Study of Modified mRNA Vaccines in Healthy Adults

Simultaneous mRNA COVID-19 and IIV4 Vaccination Study

Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults

Post COVID-19 Vaccination Analysis in Healthcare Worker Recipients

An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5)

Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine

The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes

A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age

COVID-19 Breakthrough Infection in Fully Vaccinated People and in People Who Received a Booster Dose

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age

Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older

Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.

Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction

A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine

High-Dose Moderna mRNA-1273 Booster Study for Lung Transplant Recipients

Vaccination for Recovered Inpatients With COVID-19 (VATICO)

A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants

Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)

Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines